Eef L Theunissen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5301398/publications.pdf

Version: 2024-02-01

63 papers	2,791 citations	201385 27 h-index	182168 51 g-index
65 all docs	65 docs citations	65 times ranked	2315 citing authors

#	Article	IF	Citations
1	Psychotomimetic symptoms after a moderate dose of a synthetic cannabinoid (JWH-018): implications for psychosis. Psychopharmacology, 2022, 239, 1251-1261.	1.5	12
2	Sex differences in acute cannabis effects revisited: Results from two randomized, controlled trials. Addiction Biology, 2022, 27, e13125.	1.4	18
3	Cannabis Use and Neuroadaptation: A Call for Î”9-Tetrahydrocannabinol Challenge Studies. Frontiers in Psychiatry, 2022, 13, 870750.	1.3	0
4	Low Doses of LSD Acutely Increase BDNF Blood Plasma Levels in Healthy Volunteers. ACS Pharmacology and Translational Science, 2021, 4, 461-466.	2.5	71
5	Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide Microdoses in Healthy Participants. Clinical Pharmacology and Therapeutics, 2021, 109, 658-666.	2.3	26
6	A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers. Journal of Psychopharmacology, 2021, 35, 398-405.	2.0	47
7	Reduced responsiveness of the reward system is associated with tolerance to cannabis impairment in chronic users. Addiction Biology, 2021, 26, e12870.	1.4	31
8	Intoxication by a synthetic cannabinoid (JWH-018) causes cognitive and psychomotor impairment in recreational cannabis users. Pharmacology Biochemistry and Behavior, 2021, 202, 173118.	1.3	11
9	The why behind the high: determinants of neurocognition during acute cannabis exposure. Nature Reviews Neuroscience, 2021, 22, 439-454.	4.9	36
10	Reply to: Managing the high: developing legislation and detection methods for cannabis impairment. Nature Reviews Neuroscience, 2021, 22, 585-585.	4.9	0
11	Phase 1 Clinical Trials in Psychopharmacology. , 2021, , 235-244.		1
12	Excretion of 4-fluoroamphetamine and three metabolites in urine after controlled oral ingestion. Journal of Pharmaceutical and Biomedical Analysis, 2020, 179, 113008.	1.4	6
13	Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study. European Neuropsychopharmacology, 2020, 41, 81-91.	0.3	62
14	Analysis of 4â€fluoroamphetamine in cerumen after controlled oral application. Drug Testing and Analysis, 2020, 12, 968-974.	1.6	4
15	Blunted highs: Pharmacodynamic and behavioral models of cannabis tolerance. European Neuropsychopharmacology, 2020, 36, 191-205.	0.3	48
16	Semiquantitative Activity-Based Detection of JWH-018, a Synthetic Cannabinoid Receptor Agonist, in Oral Fluid after Vaping. Analytical Chemistry, 2020, 92, 6065-6071.	3.2	5
17	Effect of Cannabidiol and Î”⁹-Tetrahydrocannabinol on Driving Performance. JAMA - Journal of the American Medical Association, 2020, 324, 2177.	3.8	106
18	Cocaine enhances figural, but impairs verbal â€˜flexibleâ€™ divergent thinking. European Neuropsychopharmacology, 2019, 29, 813-824.	0.3	10

#	Article	IF	Citations
19	Neurocognition and Subjective Experience Following Acute Doses of the Synthetic Cannabinoid JWH-018: Responders Versus Nonresponders. Cannabis and Cannabinoid Research, 2019, 4, 51-61.	1.5	18
20	Pharmacokinetic properties of 4â€fluoroamphetamine in serum and oral fluid after oral ingestion. Drug Testing and Analysis, 2019, 11, 1028-1034.	1.6	8
21	Cannabis induced increase in striatal glutamate associated with loss of functional corticostriatal connectivity. European Neuropsychopharmacology, 2019, 29, 247-256.	0.3	45
22	Mephedrone and Alcohol Interactions in Humans. Frontiers in Pharmacology, 2019, 10, 1588.	1.6	21
23	Pharmacokinetic properties of the synthetic cannabinoid JWHâ€018 in oral fluid after inhalation. Drug Testing and Analysis, 2018, 10, 644-650.	1.6	16
24	Excretion of metabolites of the synthetic cannabinoid JWH-018 in urine after controlled inhalation. Journal of Pharmaceutical and Biomedical Analysis, 2018, 150, 162-168.	1.4	8
25	Neurocognition and subjective experience following acute doses of the synthetic cannabinoid JWHâ€018: a phase 1, placeboâ€controlled, pilot study. British Journal of Pharmacology, 2018, 175, 18-28.	2.7	34
26	Independent elevation of peripheral oxytocin concentrations and reduction in cognitive empathy during 4â€fluoroamphetamine intoxication. Human Psychopharmacology, 2018, 33, e2680.	0.7	5
27	A single dose of cocaine enhances prospective memory performance. Journal of Psychopharmacology, 2018, 32, 883-892.	2.0	4
28	Safety Profile and Neurocognitive Function Following Acute 4-Fluoroamphetamine (4-FA) Administration in Humans. Frontiers in Pharmacology, 2018, 9, 713.	1.6	14
29	Brain reactivity to alcohol and cannabis marketing during sobriety and intoxication. Addiction Biology, 2017, 22, 823-832.	1.4	22
30	Pharmacokinetic properties of the synthetic cannabinoid JWH-018 and of its metabolites in serum after inhalation. Journal of Pharmaceutical and Biomedical Analysis, 2017, 140, 215-222.	1.4	73
31	Neurocognitive performance following acute mephedrone administration, with and without alcohol. Journal of Psychopharmacology, 2016, 30, 1305-1312.	2.0	22
32	Verbal Memory Impairment in Polydrug Ecstasy Users: A Clinical Perspective. PLoS ONE, 2016, 11, e0149438.	1.1	19
33	MDMA, cannabis, and cocaine produce acute dissociative symptoms. Psychiatry Research, 2015, 228, 907-912.	1.7	28
34	Rivastigmine but not vardenafil reverses cannabis-induced impairment of verbal memory in healthy humans. Psychopharmacology, 2015, 232, 343-353.	1.5	26
35	Psychedelic symptoms of cannabis and cocaine use as a function of trait impulsivity. Journal of Psychopharmacology, 2015, 29, 324-334.	2.0	19
36	Emotion recognition during cocaine intoxication. European Neuropsychopharmacology, 2015, 25, 1914-1921.	0.3	15

#	Article	IF	Citations
37	Memory and mood during MDMA intoxication, with and without memantine pretreatment. Neuropharmacology, 2014, 87, 198-205.	2.0	28
38	The role of P-glycoprotein in CNS antihistamine effects. Psychopharmacology, 2013, 229, 9-19.	1.5	14
39	A Randomized Trial on the Acute and Steady-State Effects of a New Antidepressant, Vortioxetine (Lu) Tj ETQq1 1 0.784314 rgBT /Ove	2.3	64
40	Influence of Ethanol on the Pharmacokinetic Properties of Â9-Tetrahydrocannabinol in Oral Fluid. Journal of Analytical Toxicology, 2013, 37, 152-158.	1.7	17
41	Psychomotor Function in Chronic Daily Cannabis Smokers during Sustained Abstinence. PLoS ONE, 2013, 8, e53127.	1.1	69
42	Medicinal Î”⁹â€tetrahydrocannabinol (dronabinol) impairs onâ€theâ€road driving performance of occasional and heavy cannabis users but is not detected in <scp>S</scp>tandard <scp>F</scp>ield <scp>S</scp>obriety <scp>T</scp>ests. Addiction, 2012, 107, 1837-1844.	1.7	91
43	Neurophysiological functioning of occasional and heavy cannabis users during THC intoxication. Psychopharmacology, 2012, 220, 341-350.	1.5	62
44	Effects of Acute MDMA Intoxication on Mood and Impulsivity: Role of the 5-HT2 and 5-HT1 Receptors. PLoS ONE, 2012, 7, e40187.	1.1	77
45	Short-Term Effects of Morning Versus Evening Dose of Hydroxyzine 50 mg on Cognition in Healthy Volunteers. Journal of Clinical Psychopharmacology, 2011, 31, 294-301.	0.7	10
46	Tolerance and cross-tolerance to neurocognitive effects of THC and alcohol in heavy cannabis users. Psychopharmacology, 2011, 214, 391-401.	1.5	125
47	Residual effects of esmirtazapine on actual driving performance: overall findings and an exploratory analysis into the role of CYP2D6 phenotype. Psychopharmacology, 2011, 215, 321-332.	1.5	32
48	Influence of ethanol on cannabinoid pharmacokinetic parameters in chronic users. Analytical and Bioanalytical Chemistry, 2011, 400, 145-152.	1.9	22
49	Acute and subchronic effects of bilastine (20 and 40â€‰mg) and hydroxyzine (50â€‰mg) on actual driving performance in healthy volunteers. Journal of Psychopharmacology, 2011, 25, 1517-1523.	2.0	50
50	Pharmacokinetic Properties of Â9-Tetrahydrocannabinol in Oral Fluid of Occasional and Chronic Users. Journal of Analytical Toxicology, 2010, 34, 216-221.	1.7	62
51	Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. Journal of Psychopharmacology, 2009, 23, 266-277.	2.0	294
52	Comparing the Stimulant Effects of the H1-Antagonist Fexofenadine With 2 Psychostimulants, Modafinil and Methylphenidate. Journal of Clinical Psychopharmacology, 2009, 29, 439-443.	0.7	21
53	Comparison of Cannabinoid Pharmacokinetic Properties in Occasional and Heavy Users Smoking a Marijuana or Placebo Joint. Journal of Analytical Toxicology, 2008, 32, 470-477.	1.7	98
54	Lack of effects between rupatadine 10â€‰mg and placebo on actual driving performance of healthy volunteers. Human Psychopharmacology, 2007, 22, 289-297.	0.7	40

#	Article	IF	Citations
55	A combined neurophysiological and behavioural study into the stimulating effects of fexofenadine on performance. Journal of Psychopharmacology, 2006, 20, 496-505.	2.0	18
56	Cognition and motor control as a function of Î”9-THC concentration in serum and oral fluid: Limits of impairment. Drug and Alcohol Dependence, 2006, 85, 114-122.	1.6	262
57	Repeated-dose effects of mequitazine, cetirizine and dexchlorpheniramine on driving and psychomotor performance. British Journal of Clinical Pharmacology, 2006, 61, 79-86.	1.1	39
58	Stimulating effects of the antihistamine fexofenadine: testing the dopamine transporter hypothesis. Psychopharmacology, 2006, 187, 95-102.	1.5	16
59	Up in Smoke: Comparability of THC Dosing across Performance Studies. Neuropsychopharmacology, 2006, 31, 2800-2801.	2.8	7
60	Stimulating Effects of H1-Antagonists. Current Pharmaceutical Design, 2006, 12, 2501-2509.	0.9	21
61	High-Potency Marijuana Impairs Executive Function and Inhibitory Motor Control. Neuropsychopharmacology, 2006, 31, 2296-2303.	2.8	322
62	Developmental changes in distinguishing concurrent auditory objects. Cognitive Brain Research, 2003, 16, 210-218.	3.3	30
63	Binding occurs at early stages of processing in children and adults. NeuroReport, 2001, 12, 1949-1954.	0.6	8